| Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates |
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago. |
zacks.com |
2025-05-06 23:30:41 |
Czytaj oryginał (ang.) |
| Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V. |
accessnewswire.com |
2025-05-06 20:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 |
NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2025. Presentation Details: Presenting Author: Andrew T. |
accessnewswire.com |
2025-04-23 14:35:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Reports Granting of Inducement Award |
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022. |
accessnewswire.com |
2025-04-16 20:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? |
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-25 12:55:32 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 |
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies for 2025. Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and transformative technologies. |
accessnewswire.com |
2025-03-18 09:00:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why |
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-12 15:01:03 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It |
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. |
seekingalpha.com |
2025-03-11 18:00:09 |
Czytaj oryginał (ang.) |
| PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study |
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint. |
zacks.com |
2025-03-11 15:20:40 |
Czytaj oryginał (ang.) |
| Overlooked Stock: PTGX |
Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock, particularly its cash pile. |
youtube.com |
2025-03-10 18:57:46 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out |
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily. |
investors.com |
2025-03-10 12:19:46 |
Czytaj oryginał (ang.) |
| Why Is Protagonist Therapeutics Stock Trading Higher On Monday? |
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). |
benzinga.com |
2025-03-10 12:04:33 |
Czytaj oryginał (ang.) |
| Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera |
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first. |
businesswire.com |
2025-03-03 08:45:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates |
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago. |
zacks.com |
2025-02-21 11:35:25 |
Czytaj oryginał (ang.) |
| Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025 Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025 Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra," said Dinesh V. |
accessnewswire.com |
2025-02-21 09:00:00 |
Czytaj oryginał (ang.) |
| Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck |
Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. |
seekingalpha.com |
2025-01-13 07:55:13 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Reports Granting of Inducement Awards |
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. |
accesswire.com |
2025-01-06 18:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 |
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-12-19 18:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 |
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-11-22 09:30:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate |
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. |
accesswire.com |
2024-11-19 09:30:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know |
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-13 15:06:16 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates |
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.58 per share a year ago. |
zacks.com |
2024-11-07 20:30:31 |
Czytaj oryginał (ang.) |
| Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024 Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025 Top line results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in Q1 2025 Development candidate nomination for oral IL-17 peptide antagonist expected in Q4 2024 Cash, cash equivalents and marketable securities of $583.3 million as of September 30, 2024, anticipated to provide cash runway through end of 2027 NEWARK, CA / ACCESSWIRE / November 7, 2024 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. "Protagonist is approaching multiple transformational events with the pending readouts of JNJ-2113 in Phase 3 psoriasis studies this year, Phase 2b ulcerative colitis study in Q1 2025, and rusfertide Phase 3 study in polycythemia vera in Q1 2025," said Dinesh V. |
accesswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting |
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024. ASH Presentation Details: Presenting author: Aaron Gerds, MD (Cleveland Clinic) Publication Number: 4559 Title: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV) Session Name: 634. |
accesswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-10-15 13:51:26 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines |
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity. |
benzinga.com |
2024-09-10 17:17:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 |
NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates |
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago. |
zacks.com |
2024-08-06 13:21:06 |
Czytaj oryginał (ang.) |
| Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase 2b ANTHEM clinical trial in moderate-to-severe ulcerative colitis expected to complete the primary endpoint portion of the study in Q4 2024 Rusfertide Phase 2 REVIVE study long-term follow-up data in polycythemia vera presented at European Hematology Association (EHA) 2024; study showed durable hematocrit control, decreased phlebotomy use, long-term tolerability and no new safety signals Rusfertide topline results from the 32-week primary endpoint of the Phase 3 VERIFY study expected in Q1 2025 Cash, cash equivalents and marketable securities of $595.4M as of June 30, 2024, anticipated to provide cash runway through end of 2027 NEWARK, CA / ACCESSWIRE / August 6, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "During the second quarter of 2024 our team made tremendous strides in the late-stage clinical development of rusfertide and also in leveraging our proprietary discovery platform for early-stage, but highly differentiated, oral peptides-based discovery programs," said Dinesh V. |
accesswire.com |
2024-08-06 11:00:00 |
Czytaj oryginał (ang.) |
| Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor |
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. |
accesswire.com |
2024-07-31 13:15:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 |
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-07-22 11:00:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-07-18 13:51:05 |
Czytaj oryginał (ang.) |
| 3 Growth Stocks No One Is Watching (But They Should Be) |
Larger-capitalization enterprises command exceptional predictability with their businesses. They're often storied franchises with globally recognizable brands that people consume on the regular. |
investorplace.com |
2024-07-11 10:00:00 |
Czytaj oryginał (ang.) |
| The 3 Best Biotech Stocks to Buy in June 2024 |
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech's high-capital requirements and rising interest rates set by the Fed. |
investorplace.com |
2024-06-05 17:35:02 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 |
NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-05-31 11:30:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress |
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024. There will also be a published abstract showing the absence of QTc prolongation with rusfertide based on the results from the thorough QT/QTc study conducted in healthy subjects. |
accesswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event |
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D. |
accesswire.com |
2024-05-07 20:10:00 |
Czytaj oryginał (ang.) |